Intellia Therapeutics, Inc. (NTLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.74+0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NTLA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Develop and commercialize lonvo-z as a one-time in vivo CRISPR gene editing treatment for hereditary angioedema, with FDA BLA submission in 2026 and U.S. launch planned for first half of 2027.
Stated as a priority in 3 of last 3 quarters. Management reported positive Phase 3 HAELO trial results showing lonvo-z reduced attacks by 87% versus placebo with a mean monthly attack rate of 0.26 vs. 2.10, and 62% of patients were attack free and therapy free versus 11% placebo. The rolling BLA submission was initiated and FDA acceptance is anticipated in second half of 2026 with a planned U.S. launch in first half of 2027. The trajectory is delivering on clinical and regulatory milestones.
“Positive Phase 3 HAELO clinical data for lonvo-z; anticipate FDA acceptance of BLA in second half of 2026 and U.S. launch in first half of 2027.”
“Presented positive Phase 3 HAELO topline clinical data for lonvo-z; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027.”
“Announced positive topline results from Phase 3 HAELO trial of lonvo-z; initiated rolling BLA submission; preparing for potential U.S. launch in first half of 2027.”
Maintain sufficient cash resources to fund operations at least into 2028, supporting clinical development and commercial launch activities.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities increased from $605.1 million at 2025-Q4 to $628.4 million at 2026-Q2. Management consistently states that existing cash resources are expected to fund operations at least into 2028 and beyond lonvo-z's anticipated U.S. commercial launch in first half of 2027. The trajectory shows stable to improving cash position supporting this priority.
“Existing cash resources expected to fund operations at least into 2028 and beyond lonvo-z's anticipated U.S. commercial launch in first half of 2027.”
“Existing cash resources expected to fund operations at least into 2028 and beyond lonvo-z's anticipated U.S. commercial launch in first half of 2027.”
“Existing cash resources expected to fund operations at least into 2028.”
Progress enrollment and clinical development of nexiguran ziclumeran (nex-z) in Phase 3 trials for transthyretin amyloidosis with cardiomyopathy and hereditary ATTR amyloidosis with polyneuropathy.
Stated as a priority in 3 of last 3 quarters. Management reports enrollment reinitiated and advancing in nex-z Phase 3 trials, with MAGNITUDE-2 enrollment expected to complete in second half of 2026. FDA clinical holds were lifted prior to 2026-Q1. The trajectory shows progress in clinical development and enrollment consistent with stated plans.
“Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment expected to be completed in second half of 2026.”
“Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively; plan to complete enrollment in MAGNITUDE-2 in second half of 20…”
“FDA lifted clinical holds on MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z; patient screening activities advancing.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 1.11x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
20 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.